When it comes to Nrf2, there can be such a thing as “too much of a good thing.”
Even though Nrf2 activation is useful in many cases, having the Nrf2 pathway turned on ALL THE TIME can be harmful to the body.
The dark side of Nrf2 is that mutated cells or cancer cells can use the mutated form of a protein called Keap1 to their advantage. It will form a “shield," or a protective barrier, that would protect them from chemotherapeutic agents. The immune system won’t be able to do anything about it.
So, if the Keap1-Nrf2 pathway is mutated, it can make the tumor grow faster and become more resistant.
![](https://i.shgcdn.com/f542d272-e6f5-4d73-b5e6-3e2ae4c00b67/-/format/auto/-/preview/3000x3000/-/quality/lighter/)
Keap1, the protein, contains multiple sensors. If these sensors together with the receptor regions are activated, the body will release Nrf2, and it will pass into the nucleus. When the Nrf2 enters the nucleus, it will bind itself to the region called the Antioxidant Response Element. There are certain genes here. These genes are important because they have antioxidant properties. They are the ones who get rid of oxidative stress. If we lack Keap1, the Nrf2 pathway will remain activated at all times. This can be a serious problem for our body.
Why?
Because mutations can cause cancer. Nrf2 cancer research shows that mutations can increase the risk of cancer.
Summary: if the Keap1 protein is mutated, it can cause cancer. The Nrf2 protein can’t protect the body from this mutated protein. What early studies indicate is that having the Nrf2 pathway activated constantly can actually increase the chance of mortality, hypertension, and albuminuria (a sign of kidney disease). Which is the complete opposite of what we want.
That’s where the hidden benefit of molecular hydrogen comes into play. Molecular hydrogen is a selective Nrf2 activator.
Meaning:
It works only when the body needs it.
So instead of constantly activating the Nrf2 pathway, molecular hydrogen initiates the Nrf2 pathway only in times of
cellular stress.
In other words: